おすすめの製品
由来生物
goat
品質水準
結合体
FITC conjugate
抗体製品の状態
purified antibody
抗体製品タイプ
primary antibodies
クローン
polyclonal
化学種の反応性
human
メーカー／製品名
Chemicon®
テクニック
immunofluorescence: suitable
immunohistochemistry: suitable
輸送温度
wet ice
特異性
Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells
免疫原
Hexon from adenovirus type 5.
アプリケーション
Research Category
感染症
感染症
Research Sub Category
感染症－ウイルス
感染症－ウイルス
Anti-Adenovirus Antibody, FITC-conjugated is an antibody against Adenovirus for use in IF, IH.
Direct FA staining of target antigens in a permissive tissue culture system. Suggested dilution: 1:10-1:50. Acetone fixation of the antigen source is recommended prior to staining.
Optimal working dilutions must be determined by end user
Optimal working dilutions must be determined by end user
物理的形状
IgG fraction conjugated to FITC. In PBS (0.01 M, pH 7.2) containing 10 mg/mL BSA and 0.1% sodium azide
保管および安定性
Maintain at 2-8°C for 3 months or at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. Store under subdued light.
法的情報
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
AB1056F:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Rachael Mooney et al.
Molecular therapy oncolytics, 12, 79-92 (2019-02-06)
Oncolytic virotherapy is a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the clinic has been hampered by rapid immune-mediated clearance or neutralization of the virus, which reduces viral access to tumor foci. To
N Yawata et al.
Mucosal immunology, 9(1), 159-170 (2015-06-18)
The most severe form of virus-induced inflammation at the ocular surface is epidemic keratoconjunctivitis (EKC), often caused by group D human adenoviruses (HAdVs). We investigated the dynamics and mechanisms of changes in natural killer (NK) cell types in the human
In situ adenovirus vaccination engages T effector cells against cancer.
Sebastian Tuve, Ying Liu, Khajornsak Tragoolpua, Jeffrey Daniel Jacobs et al.
Vaccine null
Comparison of adenoviruses from species B, C, E, and F after intravenous delivery.
Daniel Stone, Ying Liu, Zong-Yi Li, Sebastian Tuve, Robert Strauss, Andre Lieber
Molecular Therapy null
Sacha Robert et al.
Viruses, 16(4) (2024-04-27)
Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）